M&A / Deals Gilead strikes again, penning $5bn deal to buy Tubulis PharmaphorumGilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaphorum Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront. M&A / DealsRead full story Post navigation Previous: AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat SolidifiesNext: 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026